Praxis Precision Medicines Inc [PRAX] stock prices are down -6.06% to $184.56 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PRAX shares have gain 8.69% over the last week, with a monthly amount drifted -8.18%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Praxis Precision Medicines Inc [NASDAQ: PRAX] stock has seen the most recent analyst activity on November 19, 2025, when BTIG Research initiated its Buy rating and assigned the stock a price target of $424. On May 07, 2025, Chardan Capital Markets initiated with a Buy rating and assigned a price target of $80 on the stock. H.C. Wainwright reiterated its Buy rating and decreased its price target to $105 on March 03, 2025. Deutsche Bank initiated its recommendation with a Buy and recommended $111 as its price target on February 11, 2025. Oppenheimer started tracking with a Outperform rating for this stock on August 05, 2024, and assigned it a price target of $134. In a note dated June 24, 2024, Needham initiated an Buy rating and provided a target price of $145 on this stock.
The stock price of Praxis Precision Medicines Inc [PRAX] has been fluctuating between $26.70 and $206.71 over the past year. Currently, Wall Street analysts expect the stock to reach $298 within the next 12 months. Praxis Precision Medicines Inc [NASDAQ: PRAX] shares were valued at $184.56 at the most recent close of the market. An investor can expect a potential return of 61.47% based on the average PRAX price forecast.
Analyzing the PRAX fundamentals
The Praxis Precision Medicines Inc [NASDAQ:PRAX] reported sales of 7.46M for trailing twelve months, representing a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -34.98%, Pretax Profit Margin comes in at -32.33%, and Net Profit Margin reading is -32.33%. To continue investigating profitability, this company’s Return on Assets is posted at -0.55, Equity is -0.6 and Total Capital is -0.67. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 179.96 points at the first support level, and at 175.35 for the second support level. However, for the 1st resistance point, the stock is sitting at 192.37, and for the 2nd resistance point, it is at 200.18.
Ratios To Look Out For
It’s worth pointing out that Praxis Precision Medicines Inc [NASDAQ:PRAX]’s Current Ratio is 5.18. As well, the Quick Ratio is 5.18, while the Cash Ratio is 3.24. Considering the valuation of this stock, the price to sales ratio is 618.68, the price to book ratio is 11.37.
Transactions by insiders
Recent insider trading involved Nemiroff Alex, General Counsel and Secretary, that happened on Nov 20 ’25 when 25130.0 shares were sold. Principal Accounting Officer, Mastrocola Lauren completed a deal on Nov 20 ’25 to sell 13600.0 shares. Meanwhile, Officer Nemiroff Alex bought 25130.0 shares on Nov 20 ’25.
